• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    6/3/24 4:31:11 PM ET
    $BGXX
    $BIMI
    $CADL
    $CCM
    Medicinal Chemicals and Botanical Products
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $BGXX alert in real time by email

    Gainers

    • FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million.
    • Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million.
    • RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million.
    • Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million.
    • Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock rose 5.65% to $1.31. The company's market cap stands at $24.9 million.

    Losers

    • Bright Green (NASDAQ:BGXX) stock fell 7.4% to $0.26 during Monday's after-market session. The market value of their outstanding shares is at $49.6 million.
    • Nanoviricides (AMEX:NNVC) stock decreased by 6.67% to $2.24. The company's market cap stands at $26.4 million.
    • Concord Medical Services (NYSE:CCM) shares fell 6.35% to $0.74. The company's market cap stands at $32.1 million.
    • BIMI Holdings (NASDAQ:BIMI) stock decreased by 6.3% to $1.19. The company's market cap stands at $16.6 million.
    • Inotiv (NASDAQ:NOTV) shares declined by 6.0% to $2.04. The company's market cap stands at $52.9 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock declined by 5.74% to $0.26. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX
    $BIMI
    $CADL
    $CCM

    CompanyDatePrice TargetRatingAnalyst
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    RAPT Therapeutics Inc.
    $RAPT
    1/9/2026$95.00Overweight
    Piper Sandler
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Scholar Rock Holding Corporation
    $SRRK
    11/18/2025$42.00Outperform
    Wolfe Research
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    RAPT Therapeutics Inc.
    $RAPT
    10/27/2025$70.00Buy
    Guggenheim
    RAPT Therapeutics Inc.
    $RAPT
    10/20/2025$55.00Neutral → Overweight
    Analyst
    RAPT Therapeutics Inc.
    $RAPT
    10/13/2025$35.00Overweight
    Barclays
    More analyst ratings

    $BGXX
    $BIMI
    $CADL
    $CCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

    Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert

    3/17/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    3/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026Company announced investigational new drug (IND) clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study.Entered into a $130 million term loan facility with Tri

    3/12/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    3/27/26 1:02:05 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inotiv Inc. filed SEC Form 8-K: Other Events

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/23/26 7:41:57 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on RAPT Therapeutics with a new price target

    Piper Sandler initiated coverage of RAPT Therapeutics with a rating of Overweight and set a new price target of $95.00

    1/9/26 9:07:04 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:33 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:12 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    3/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany Secured new debt facility, providing up to $

    3/3/26 7:00:00 AM ET
    $OWL
    $SRRK
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Leadership Updates

    Live Leadership Updates

    View All

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

    NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. "Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "He has effectively

    6/23/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $BIMI
    $CADL
    $CCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care